There are currently 214 clinical trials in Worcester, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Massachusetts Medical School, University of Massachusetts Memorial Medical Center, UMASS Memorial Medical Center and UMass Memorial Medical Center - University Campus. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Asthma Link Effectiveness Trial: Cluster Randomized Controlled Trial
NCT06388460
Recruiting
The goal of this cluster RCT is to determine the effectiveness of Asthma Link, a school supervised asthma therapy program, compared with an educational asthma workbook, in improving asthma symptoms for children with poorly controlled asthma aged 5-14.
Gender:
All
Ages:
Between 5 years and 14 years
Trial Updated:
04/23/2024
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Childhood Asthma
Register for Updates
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351
Recruiting
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/23/2024
Locations: Vitreo Retinal Associates-Worcester, Worcester, Massachusetts
Conditions: Geographic Atrophy
Register for Updates
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
NCT04878432
Recruiting
Main objective of this study is to describe and evaluate safety and efficacy of MBG453 (sabatolimab) in combination with FDA approved HMAs of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/22/2024
Locations: Uni of Massachusetts Medical Center, Worcester, Massachusetts
Conditions: Myelodysplastic Syndrome (MDS)
Register for Updates
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
04/22/2024
Locations: University of Massachusetts, Worcester, Massachusetts
Conditions: Aortic Stenosis
Register for Updates
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625
Recruiting
This phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexa... Read More
Gender:
All
Ages:
Between 365 days and 31 years
Trial Updated:
04/20/2024
Locations: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Register for Updates
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628
Recruiting
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Gender:
All
Ages:
Between 1 year and 21 years
Trial Updated:
04/19/2024
Locations: UMass Memorial Medical Center - University Campus, Worcester, Massachusetts
Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Register for Updates
Dotarem vs Gadobutrol Contrast for Breast MRI
NCT03730051
Recruiting
In this randomized clinical trial, the investigators expect to demonstrate that the MRI contrast agent Dotarem is not less effective in contrast enhancement of breast lesions then Gadavist. Participants will be randomized to receive either Dotarem or Gadavist. In all cases, inclusion criteria will require patients having undergone or scheduled or most likely to be scheduled to undergo tissue sampling with histology results available. The patients will be prospectively and consecutively identifie... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: UMass Medical School, Worcester, Massachusetts
Conditions: Breast Diseases
Register for Updates
Perimodiolar Implant Performance in Adults With Low-Frequency Residual Hearing
NCT04741009
Recruiting
The purpose of the feasibility study is to investigate hearing performance (audiometry and speech perception) using the CI632 in a group of adults (n=15) with low-frequency residual hearing who meet inclusion criteria.
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
04/19/2024
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Sensorineural Hearing Loss, Low-Frequency Residual Hearing
Register for Updates
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
NCT05093634
Recruiting
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: POMC or PCSK1 (Sub-study 035a) LEPR (Sub-study 035b) SRC1 (Sub-study 035c) SH2B1 (Sub-study 035d) The objectives and endpoints are identical for these sub-studies.
Gender:
All
Ages:
Between 6 years and 65 years
Trial Updated:
04/19/2024
Locations: UMASS Memorial Medical Center, Worcester, Massachusetts
Conditions: Obesity, Genetic Obesity
Register for Updates
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: UMass Memorial Medical Center, Worcester, Massachusetts
Conditions: Focal Onset Seizures
Register for Updates
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017
Recruiting
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/19/2024
Locations: University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts
Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Register for Updates